Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses
Clinical Scorecard: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses
At a Glance
Category Detail
Condition Multiple Sclerosis with residual disease in relapse-free phase Key Mechanisms Enhancement of the endocannabinoid system Target Population Patients with multiple sclerosis experiencing residual symptoms despite absence of relapses Care Setting Neurology outpatient and specialized MS care centers
Key Highlights
Focus on improving residual disease symptoms in relapse-free multiple sclerosis patients. Therapeutic strategy involves modulation of the endocannabinoid system. Collaboration between healthcare communication agency and authors supported by Almirall S.p.A. Guideline-Based Recommendations
Diagnosis
Identify residual disease symptoms in relapse-free multiple sclerosis patients. Management
Consider therapeutic approaches targeting the endocannabinoid system to address residual symptoms. Monitoring & Follow-up
Regular assessment of residual symptom progression and response to endocannabinoid system modulation. Risks
No specific risks detailed in the correction notice. Patient & Prescribing Data
Relapse-free multiple sclerosis patients with residual disease symptoms
Endocannabinoid system enhancement represents a potential therapeutic avenue; specific prescribing data not provided.
Clinical Best Practices
Collaborate with multidisciplinary teams for comprehensive management of residual symptoms. Ensure transparent disclosure of funding and potential conflicts of interest in clinical research. Maintain patient-centered monitoring to evaluate efficacy and safety of endocannabinoid-targeted therapies. References
